9 N -substituted 6-11 bicyclic erythromycin derivatives

Details 9 N -substituted 6-11 bicyclic erythromycin derivatives 9 N -substituted 6-11 bicyclic erythromycin derivatives

2007-09-04

2007-09-04

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S007400

Reexamination Certificate

active

11031465

ABSTRACT:
The present invention discloses compounds of formula I, II, III, or IV, or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof:which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

REFERENCES:
patent: 4990602 (1991-02-01), Morimoto et al.
patent: 5403923 (1995-04-01), Kashimura et al.
patent: 5444051 (1995-08-01), Agouridas et al.
patent: 5527780 (1996-06-01), Agouridas et al.
patent: 5631355 (1997-05-01), Asaka et al.
patent: 5686587 (1997-11-01), Yang
patent: 5780605 (1998-07-01), Or et al.
patent: 5866549 (1999-02-01), Or et al.
patent: 5922683 (1999-07-01), Or et al.
patent: 5969161 (1999-10-01), Bonnet et al.
patent: 6046171 (2000-04-01), Or et al.
patent: 6054435 (2000-04-01), Or et al.
patent: 6075133 (2000-06-01), Or et al.
patent: 6124269 (2000-09-01), Phan et al.
patent: 6274715 (2001-08-01), Or et al.
patent: 6355620 (2002-03-01), Ma et al.
patent: 6399582 (2002-06-01), Hlasta et al.
patent: 6645941 (2003-11-01), Wang et al.
patent: 6764998 (2004-07-01), Wang et al.
patent: 6878691 (2005-04-01), Or et al.
patent: 2004/0053861 (2004-03-01), Or et al.
patent: 2004/0157787 (2004-08-01), Or et al.
patent: 2004/0171818 (2004-09-01), Xu et al.
patent: 2004/0266998 (2004-12-01), Or et al.
patent: 2005/0009761 (2005-01-01), Or et al.
patent: 2005/0009763 (2005-01-01), Or et al.
patent: 2005/0014707 (2005-01-01), Wang et al.
patent: 2005/0159370 (2005-07-01), Or et al.
patent: WO99/21864 (1999-05-01), None
patent: WO 01/14397 (2001-03-01), None
patent: WO 03/042228 (2003-05-01), None
U.S. Appl. No. 11/257,680, filed Oct. 25, 2005, Wang et al.
U.S. Appl. No. 11/154,260, filed Jun. 16, 2005, Deqiang Niu et al.
U.S. Appl. No. 11/029,640, filed Jan. 5, 2005, Nha Huu Vo et al.
U.S. Appl. No. 11/122,251, filed May 4, 2005, Guoqiang Wang et al.
U.S. Appl. No. 11/057,476, filed Feb. 14, 2005, Datong Tang et al.
8thInternational Antibacterial Drug Discovery and Development Summit,Strategic Research Institute,Mar. 24-25, 2003, Princeton, NJ.
Bright, G. Michael, et al., “Synthesis, In Vitro and In Vivo Activity of Novel 9-Deoxo-9a-AZA-9a-Homoerythromycin A Derivatives; A New Class of Macrolide Antibiotics, the Azalides,”J. of Antibiotics, XLI(8): 1029-1047 (1988).

Affiliated with

Also associated with

Rating

9 N -substituted 6-11 bicyclic erythromycin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 9 N -substituted 6-11 bicyclic erythromycin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 9 N -substituted 6-11 bicyclic erythromycin derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3788308